SLAS Discovery

Papers
(The H4-Index of SLAS Discovery is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones148
RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery119
Targeting RNA with Small Molecules: Identification of Selective, RNA-Binding Small Molecules Occupying Drug-Like Chemical Space64
Advances in Antibody–Drug Conjugate Design: Current Clinical Landscape and Future Innovations48
Probing the SAM Binding Site of SARS-CoV-2 Nsp14 In Vitro Using SAM Competitive Inhibitors Guides Developing Selective Bisubstrate Inhibitors48
A Critical and Concise Review of Mass Spectrometry Applied to Imaging in Drug Discovery40
MALDI-TOF Mass Spectrometry-Based High-Throughput Screening for Inhibitors of the Cytosolic DNA Sensor cGAS38
High-Throughput Screening for Drugs That Inhibit Papain-Like Protease in SARS-CoV-238
Comparison of Cell and Organoid-Level Analysis of Patient-Derived 3D Organoids to Evaluate Tumor Cell Growth Dynamics and Drug Response36
Cryo-EM: The Resolution Revolution and Drug Discovery35
Recommended Guidelines for Developing, Qualifying, and Implementing Complex In Vitro Models (CIVMs) for Drug Discovery32
Phenotypic Profiling of Reference Chemicals across Biologically Diverse Cell Types Using the Cell Painting Assay32
High-Throughput Mass Spectrometry for Hit Identification: Current Landscape and Future Perspectives32
High-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer Organoids29
Discovery of Drug-Like Ligands for the Mac1 Domain of SARS-CoV-2 Nsp329
A Mass Spectrometric Assay of METTL3/METTL14 Methyltransferase Activity28
Development of a High-Throughput Screening Assay to Identify Inhibitors of the SARS-CoV-2 Guanine-N7-Methyltransferase Using RapidFire Mass Spectrometry28
Acoustic Ejection Mass Spectrometry: A Fully Automatable Technology for High-Throughput Screening in Drug Discovery25
Selecting Approaches for Hit Identification and Increasing Options by Building the Efficient Discovery of Actionable Chemical Matter from DNA-Encoded Libraries24
A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-1924
Identification of Compounds for Butyrylcholinesterase Inhibition24
Target-Directed Approaches for Screening Small Molecules against RNA Targets22
Target Validation Using PROTACs: Applying the Four Pillars Framework22
0.031720876693726